- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
At a Glance While a kidney transplant is the most clinically- and cost-effective treatment for end stage kidney disease (ESKD), systemic barriers and social determinants of health frequently leave underserved communities behind. Accelerating the path to transplant can help close persistent gaps in chronic disease management while also reducing the time patients spend on dialysis. […] The post Building Bridges: How DaVita Transplant Liaisons are Working to Close the Kidney Gap appeared first on Newsroom.
More than 10,000 members will get added support aimed at delaying or preventing dialysis and reducing hospitalizations DENVER, Aug. 25, 2026 /PRNewswire/ -- DaVita today announced a new... The post DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease appeared first on Investor.
More than 10,000 members will get added support aimed at delaying or preventing dialysis and reducing hospitalizations DENVER, Aug. 25, 2026 /PRNewswire/ -- DaVita today announced a new... The post DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease appeared first on Newsroom.
As DaVita expands access to Expanded hemodialysis (HD), some patients who have recently started the treatment have shared positive personal experiences, including changes in how they feel day to day. These individual stories reflect patients’ perspectives and experiences and should not be interpreted as evidence of clinical outcomes for all patients. Real-World Patient Experiences The […] The post Patients Share Their Experiences With Expanded HD appeared first on Newsroom.
DaVita will also continue hemodiafiltration (HDF) pilots to advance a comprehensive approach to middle molecule clearance. In the ongoing pursuit of improved outcomes in kidney care, few targets have been as stubborn as the middle molecule gap. When middle molecules — larger uremic toxins that are not effectively cleared during standard high-flux dialysis — accumulate, […] The post DaVita Rapidly Scales Expanded HD to Target Hard-to-Remove Toxins appeared first on Newsroom.
DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2026. "Thanks to the outstanding efforts of our teammates, we had another positive quarter for both... The post DaVita Inc. 2nd Quarter 2026 Results appeared first on Investor.
DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2026. "Thanks to the outstanding efforts of our teammates, we had another positive quarter for both... The post DaVita Inc. 2nd Quarter 2026 Results appeared first on Newsroom.
By: Michael Moustakakis, MD, Group Medical Director for DaVita Extreme heat waves trigger standard public health advice everywhere: Drink plenty of water. For the general public, it’s a vital strategy to stay healthy and avoid heatstroke. But for the approximately 550,000 Americans living with end stage kidney disease (ESKD) and managing life on dialysis, this […] The post Summer Heat, Hydration and ESKD: Mitigating Health Risks appeared first on Newsroom.
DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 4, 2026, at 5:00 p.m. Eastern Time. The company plans... The post DaVita Inc. Schedules 2nd Quarter 2026 Investor Conference Call appeared first on Investor.
DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 4, 2026, at 5:00 p.m. Eastern Time. The company plans... The post DaVita Inc. Schedules 2nd Quarter 2026 Investor Conference Call appeared first on Newsroom.
